Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors

NCT00455052 is registered in ClinicalTrials.gov with Mersana Therapeutics as lead sponsor.

NCT NCT00455052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00455052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous XMT-1001 in Patients With Advanced Solid Tumors
Lead sponsor
Mersana Therapeutics
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2011
Completion date
December 31, 2011
Enrollment
30 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, small cell lung cancer